BRALTUS

This brand name is authorized in Australia, Austria, Croatia, Estonia, Ireland, Lithuania, New Zealand, Poland, Spain, UK.

Active ingredients

The drug BRALTUS contains one active pharmaceutical ingredient (API):

1	Tiotropium UNII XX112XZP0J - TIOTROPIUM BROMIDE ANHYDROUS
	Tiotropium is a long-acting, specific, muscarinic receptor antagonist, in clinical medicine often called an anticholinergic. By binding to the muscarinic receptors in the bronchial smooth musculature, tiotropium inhibits the cholinergic (bronchoconstrictive) effects of acetylcholine, released from parasympathetic nerve endings.
	Read more about Tiotropium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRALTUS Inhalation powder, hard capsule	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03BB04	Tiotropium bromide	R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BB Anticholinergics
Discover more medicines within R03BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11892X
EE	Ravimiamet	1667404, 1667415, 1667426, 1726578
ES	Centro de información online de medicamentos de la AEMPS	80981
GB	Medicines & Healthcare Products Regulatory Agency	335950, 377161, 377438, 381209
HR	Agencija za lijekove i medicinske proizvode	HR-H-818206056
IE	Health Products Regulatory Authority	61508
LT	Valstybinė vaistų kontrolės tarnyba	1074773, 1074774, 1074775, 1080688
NZ	Medicines and Medical Devices Safety Authority	20519
PL	Rejestru Produktów Leczniczych	100329620, 100423097